doripenem + piperacillin + tazobactam

**doripenem + piperacillin + tazobactam** is a hypothetical triple antibiotic combination consisting of three separate agents: doripenem (a carbapenem), piperacillin (a ureidopenicillin), and tazobactam (a β-lactamase inhibitor). Each agent is a broad-spectrum antibacterial, commonly used in hospital settings for severe or resistant bacterial infections. Doripenem acts by inhibiting bacterial cell wall synthesis via binding to penicillin-binding proteins. Piperacillin also inhibits cell wall synthesis by binding to penicillin-binding proteins and has broad activity, especially against Pseudomonas species. Tazobactam acts as a β-lactamase inhibitor, protecting piperacillin from enzymatic degradation by β-lactamase-producing bacteria. This three-drug combination is not a standard or approved fixed-dose formulation; while piperacillin + tazobactam is widely used and available under brand names like Zosyn, and doripenem is sometimes compared with or used sequentially with piperacillin/tazobactam in clinical studies, there is no evidence of an approved or marketed product containing all three agents in a single combination.